Abgenix slashes staff, concentrates on panitumumab

Abgenix plans to lay off about 15 percent of its work force -- some 58 employees -- as it concentrates its research efforts on pipeline development. As part of the restructuring, Abgenix will sublease research space in California. It is retaining trial and manufacturing facilities. Officials say they will focus more on its most promising drug candidate -- panitumumab -- which is being developed with Amgen as a cancer therapy.

"We concluded from our strategic review that we have excess capacity, primarily in our research personnel and facilities, and believe we will maximize efficiency by consolidating our research and preclinical activities in our Canadian location," said Bill Ringo, president and CEO of Abgenix. "These adjustments will enable us to expand our development and commercial operations later this year and next, as we prepare for the manufacturing and potential co-promotion of panitumumab with our partner, Amgen."

- read this press release for more

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.